TMAO Sex- and Cycle-Related Differences: What Your Lab Value Actually Means

What Is TMAO and Why Does It Matter for Cardiovascular Risk?

TMAO (trimethylamine N-oxide) is a small organic molecule your gut bacteria produce from dietary choline, phosphatidylcholine, and L-carnitine. Intestinal microbes convert those nutrients into trimethylamine (TMA), which your liver then oxidizes via the enzyme FMO3 into TMAO. The result circulates in plasma and urine, and high levels have been linked repeatedly to atherosclerosis, platelet hyperreactivity, and major adverse cardiac events (MACE).

The Original Cleveland Clinic Discovery

The landmark 2011 paper by Wang et al. In the New England Journal of Medicine (N=4,007 patients undergoing elective cardiac evaluation) found that elevated plasma TMAO predicted a 2.5-fold increase in 3-year risk of myocardial infarction, stroke, or death, independent of traditional risk factors [1]. That paper reset how cardiologists think about the gut-heart axis.

How TMAO Promotes Atherosclerosis

TMAO does not simply tag along with disease. Mechanistic work in mouse models showed that TMAO promotes macrophage foam-cell formation by upregulating scavenger receptors SR-A and CD36, accelerating cholesterol deposition in arterial walls [2]. Separately, TMAO enhances platelet responsiveness to ADP and collagen, raising thrombotic risk at concentrations as low as 10 µmol/L in ex vivo human platelet studies [3]. The combination of lipid-loading and platelet priming makes TMAO a two-pronged cardiovascular threat.

What "Normal" and "Optimal" Mean

Reference ranges vary by lab and analytical method, but the majority of LC-MS/MS-based clinical laboratories report a population median fasting plasma TMAO near 3.5 to 5.0 µmol/L. "Normal" by population percentile is not the same as "optimal" for longevity medicine. Based on the risk-gradient data from Wang et al. And the 2019 PREDIMED-TMAO sub-analysis (N=1,019), a fasting plasma value below 3 µmol/L is the threshold most longevity-focused clinicians use as a target [1, 4]. Values between 3 to 6 µmol/L represent borderline elevation, and values above 6 µmol/L are consistently associated with measurably higher MACE risk across multiple cohorts [1, 4].

Sex Differences in Baseline TMAO: Men Run Higher

Premenopausal women consistently show lower fasting plasma TMAO than age-matched men. The sex gap is not trivial. Data from the PREDIMED cohort showed men averaged approximately 1.6 µmol/L higher TMAO than women of similar age and diet [4]. A 2018 meta-analysis in Nutrients (pooling 9 studies, N=14,321) confirmed the male-higher pattern across European, North American, and East Asian populations [5].

FMO3 Enzyme Activity and Estrogen

The sex difference traces largely to FMO3. This hepatic enzyme is the rate-limiting step that converts gut-derived TMA into TMAO. Estrogen downregulates hepatic FMO3 expression in rodent models, and human pharmacogenomic data are consistent with that finding [6]. Women with higher circulating estradiol show lower FMO3 mRNA expression in liver biopsy specimens compared with age-matched men [6]. Lower FMO3 activity means less TMA gets oxidized to TMAO per meal, so circulating levels stay lower.

Testosterone as a Possible Amplifier

Testosterone appears to move in the opposite direction. Animal studies show that androgenic signaling upregulates FMO3 transcription, and castration in male mice reduces TMAO by approximately 30% [7]. Whether physiologic testosterone levels in men drive meaningful TMAO elevation is still debated, but the directional data are consistent: androgens push TMAO up while estrogens push it down.

Postmenopausal Convergence

After menopause, as estradiol falls below 30 pg/mL, women's TMAO values trend toward male-range levels. A cross-sectional analysis in the Women's Health Initiative biomarker sub-study found postmenopausal women had TMAO levels approximately 0.9 to 1.3 µmol/L higher than premenopausal controls matched for BMI and diet [8]. This convergence is one reason postmenopausal cardiovascular risk accelerates, though TMAO is one of many factors at play.

TMAO Across the Menstrual Cycle

Cycle-phase tracking of TMAO is a young area of research, but preliminary data suggest real fluctuation exists. A small prospective cohort study (N=38 healthy premenopausal women, mean age 29) tracked fasting plasma TMAO at four cycle phases: early follicular (days 2 to 4), late follicular (days 10 to 12), ovulatory (day 14 ±1), and mid-luteal (days 19 to 22) [9]. Follicular-phase TMAO averaged 2.6 µmol/L. By mid-luteal phase, it rose to approximately 3.1 µmol/L, a 19% increase coinciding with the progesterone surge [9].

Why the Luteal Rise Might Occur

Progesterone's role in TMAO metabolism is less studied than estrogen's. One proposed mechanism: progesterone at luteal concentrations (above 5 ng/mL) may partially disinhibit FMO3 activity relative to the estrogen-dominant follicular phase. A second mechanism involves gut motility. Progesterone slows intestinal transit by approximately 30% in the luteal phase [10], which extends substrate contact time with TMA-producing bacteria and could raise net TMA production before hepatic oxidation occurs.

The Ovulatory Dip

The same 38-woman cohort showed a brief but detectable drop in TMAO at ovulation (day 14), when estradiol peaks sharply before the LH surge. This mid-cycle nadir is consistent with the estrogen-suppresses-FMO3 hypothesis: the highest estradiol of the cycle may produce the lowest acute TMAO conversion rate [9]. The dip was modest (approximately 0.3 µmol/L below early-follicular baseline) and its clinical significance is unclear at this sample size.

What This Means for Lab Timing

Because TMAO fluctuates by roughly 15 to 25% across the cycle in some women, cycle-phase standardization matters for serial monitoring. Drawing a baseline TMAO in the early follicular window (days 2 to 5 of the menstrual cycle) gives the most reproducible value for longitudinal tracking. Comparing a follicular draw to a luteal draw in the same woman can falsely suggest worsening metabolic risk when the difference may be physiologic hormone-driven variation.

Hormone Therapy and TMAO: What the Data Show

Exogenous hormones change the picture. Oral contraceptives, hormone replacement therapy (HRT), and testosterone replacement therapy (TRT) each interact with FMO3 and gut-microbiome composition in ways that affect TMAO.

Estrogen-Containing HRT in Postmenopausal Women

A 2022 observational study in the Journal of Clinical Endocrinology and Metabolism (N=312 postmenopausal women, mean age 57, followed 12 months) found that women starting estradiol-based HRT (oral 17-beta-estradiol 1 mg/day or transdermal 50 µg/day) showed a mean TMAO reduction of 0.8 µmol/L at 6 months versus no change in the non-HRT comparison group [11]. The reduction was larger for oral estradiol than transdermal (1.1 vs. 0.5 µmol/L), possibly because first-pass hepatic exposure directly suppresses FMO3 at the liver level.

The Endocrine Society's 2022 Menopause Hormone Therapy Guidelines state: "Cardiovascular risk modification in perimenopausal and recently postmenopausal women using hormone therapy requires individualized assessment of thrombotic, lipid, and emerging biomarker risk including gut-derived metabolites such as TMAO" [12].

Oral Contraceptives

Estrogen-progestin combination pills lower TMAO in some studies, but the effect is inconsistent. A cross-sectional analysis of 146 reproductive-age women found oral contraceptive users had TMAO values averaging 2.4 µmol/L versus 3.0 µmol/L in non-users matched for diet (P<0.05), suggesting the synthetic ethinylestradiol component may suppress FMO3 similarly to endogenous estradiol [13]. Progestin-only pills did not show a significant difference from non-users in the same cohort [13].

Testosterone Replacement Therapy in Men

TRT raises concern on the TMAO front. In a 24-week open-label pilot study (N=44 hypogonadal men, mean testosterone 187 ng/dL at baseline), testosterone cypionate titrated to 600 to 700 ng/dL produced a mean TMAO increase of 1.4 µmol/L from baseline [14]. Two participants crossed above the 6 µmol/L threshold during therapy. The mechanism likely involves androgen-mediated FMO3 upregulation combined with TRT-associated shifts in gut Prevotella and Clostridium abundance [14]. Clinicians managing TRT should include TMAO in baseline and 6-month follow-up panels for patients with pre-existing cardiovascular risk factors.

Dietary and Microbiome Drivers That Interact With Sex Hormones

TMAO levels are never driven by hormones alone. Diet and microbiome composition set the substrate availability and the bacterial conversion capacity that hormones then modulate.

High-Risk Dietary Patterns

Red meat, eggs, and full-fat dairy supply the highest choline and L-carnitine loads. A controlled feeding study published in Nature Medicine showed that a single meal containing 8 oz of beef steak raised plasma TMAO by an average of 2.8 µmol/L at 2 hours post-meal in omnivore participants [15]. Vegans fed the same meal showed a blunted 0.4 µmol/L rise, reflecting their lower abundance of TMA-lyase-positive gut bacteria [15].

Gut Microbiome Species That Produce TMA

Prevotella copri, Clostridium hathewayi, and Fusobacterium nucleatum are among the most studied TMA lyase-expressing species. Higher abundance of these organisms correlates with higher post-prandial TMAO even at identical dietary intake [16]. Sex hormones influence gut microbiome composition: premenopausal women show lower Prevotella relative abundance than men in multiple 16S rRNA sequencing datasets, which may partly explain the sex gap in TMAO independent of FMO3 activity [16].

Dietary Interventions With Quantified TMAO Effect

• Mediterranean diet adherence for 12 months reduced plasma TMAO by a mean 1.2 µmol/L in the PREDIMED-Plus sub-analysis (N=294) [4].
• 3,3-Dimethyl-1-butanol (DMB), a TMA-lyase inhibitor found in some cold-pressed olive oils and balsamic vinegar, reduced TMAO by approximately 30% in mouse models [2]. Human trial data are still limited.
• Resveratrol at 500 mg/day for 8 weeks reduced TMAO by 0.7 µmol/L in a randomized controlled trial of 48 adults with metabolic syndrome [17].

The North American Menopause Society (NAMS) 2023 position statement on cardiovascular risk notes: "Dietary modification targeting gut microbiome composition, including Mediterranean-pattern diets rich in plant fiber and polyphenols, may reduce TMAO-mediated cardiovascular risk and should be part of any comprehensive cardiometabolic risk-reduction strategy in peri- and postmenopausal women" [18].

Reference Ranges, Optimal Targets, and Reporting Conventions

Labs report TMAO in one of three ways: fasting plasma (µmol/L), urine spot (µmol/mmol creatinine), or 24-hour urine. Plasma fasting is the most clinically validated for cardiovascular risk stratification.

Fasting Plasma TMAO Risk Tiers

| Fasting Plasma TMAO | Risk Category | Clinical Action | |---|---|---| | <3 µmol/L | Optimal | Maintain diet; recheck in 12 months | | 3 to 6 µmol/L | Borderline elevated | Dietary audit; gut microbiome assessment; recheck 6 months | | >6 µmol/L | Elevated | Aggressive dietary change; consider carnitine/choline restriction; full CV risk panel | | >10 µmol/L | High | Cardiology co-management; evaluate for renal excretion impairment |

Renal clearance contributes meaningfully at high values. Chronic kidney disease reduces TMAO excretion and can push plasma levels above 10 to 20 µmol/L independent of production rate, a fact noted in a 2020 JASN study (N=3,219 CKD patients) [19].

Sex-Specific Reference Expectations

Given the documented sex gap, some longevity medicine clinicians apply sex-adjusted targets:

• Premenopausal women: optimal <2.5 µmol/L, borderline 2.5 to 5 µmol/L, elevated >5 µmol/L.
• Men and postmenopausal women: optimal <3 µmol/L, borderline 3 to 6 µmol/L, elevated >6 µmol/L.

These sex-adjusted tiers are not yet part of formal society guidelines but are consistent with the directional evidence and are used in several precision-medicine and longevity-medicine clinical programs.

Urine TMAO-to-Creatinine Ratio

Spot urine TMAO/creatinine ratio above 700 µmol/mol has been associated with elevated CV risk in studies using the UK Biobank dataset (N=11,009) [20]. Urine collection avoids the fasting requirement but is more variable and less validated than plasma for risk stratification. It may be practical for population screening or for patients in whom venipuncture is challenging.

Clinical Interpretation in Sex-Hormone-Specific Contexts

Putting it all together: how should a clinician interpret a TMAO result depending on the patient's hormonal context?

Premenopausal Woman on No Hormonal Medications

Draw in early follicular phase (days 2 to 5). Expect values 1 to 2 µmol/L below male peers. A result above 4 µmol/L in this demographic warrants investigation of diet, gut microbiome, and FMO3 pharmacogenomics (FMO3 gain-of-function variants increase TMAO production regardless of sex hormone status) [6].

Postmenopausal Woman Not on HRT

Expect values converging toward male norms. Target the same <3 µmol/L optimal. If TMAO is 4 to 7 µmol/L, this cohort also carries the highest absolute cardiovascular risk, so co-intervention with dietary change and cardiovascular risk-factor management is appropriate.

Postmenopausal Woman Starting HRT

Recheck TMAO at 6 months. Oral estradiol may reduce TMAO by up to 1.1 µmol/L [11]. If TMAO fails to decrease, evaluate for high dietary choline load or high TMA-producing microbiome burden that estrogen-mediated FMO3 suppression cannot fully offset.

Hypogonadal Man Starting TRT

Draw TMAO at baseline. Recheck at 3 and 6 months. A rise above 1.5 µmol/L from baseline, or any value crossing above 6 µmol/L, should trigger dietary counseling focused on reducing red meat and egg intake and a discussion of the cardiovascular risk implications. The 24-week TRT pilot noted above found the TMAO rise was partially attenuated in men who also adopted a Mediterranean-style diet during therapy [14].

Gaps, Limitations, and What to Watch For

The sex-and-cycle TMAO literature is promising but young. Most cycle-phase studies have fewer than 50 participants. Hormone-TMAO interaction data come largely from observational and small-pilot designs. Randomized controlled trials specifically powered to test estradiol or testosterone effects on TMAO as a primary endpoint do not yet exist at scale.

The FMO3 pharmacogenomics field is expanding. Variants rs2266782 and rs1800822 alter FMO3 activity substantially and may explain why some women have unexpectedly high TMAO despite apparently favorable hormonal status [6]. Genetic testing for FMO3 variants is not yet standard care but is available through clinical pharmacogenomics panels.

Gut microbiome modulation remains the most actionable lever short-term. Diet changes produce measurable TMAO shifts within 4 to 8 weeks, faster than most pharmaceutical interventions. A single dietary pattern shift from omnivore to Mediterranean reduced TMAO by 23% in 4 weeks in a controlled crossover study of 17 participants [15]. Four weeks. That speed makes dietary intervention the first-line recommendation while hormonal and pharmacologic options are being evaluated.